Lode H, Madey V, Dzwillo G, Borner K, Koeppe P
J Antimicrob Chemother. 1983 May;11 Suppl B:121-6. doi: 10.1093/jac/11.suppl_b.121.
Ten healthy volunteers received 5 g azlocillin and 2 g moxalactam iv in single and combined administration. Serum and urine concentrations were measured with bioassay and HPLC (high pressure liquid chromatography), and serum bactericidal activity (SBA) was determined at 1 h and 6 h against 6 different clinical isolates. The combined applications of both antibiotics resulted in minor differences in serum kinetics and urine recovery in comparison to single administration. SBAs of both antibiotics against Enterobacteriaceae were between 1:4 and 1:8.4 for azlocillin and between 1:3 and 1:8 for moxalactam after 1 h. The combination of both beta-lactam antibiotics did not result in a decrease in SBA against any strain; rather all Enterobacteriaceae showed a slight increase of SBA at 1 h. It can be concluded from these results that combination therapy with azlocillin and moxalactam has no adverse influence on the pharmacokinetics or the bactericidal activity of either substance.
十名健康志愿者接受了单次及联合静脉注射5克阿洛西林和2克莫拉维酸。采用生物测定法和高效液相色谱法（HPLC）测定血清和尿液浓度，并在1小时和6小时时针对6种不同临床分离株测定血清杀菌活性（SBA）。与单次给药相比，两种抗生素联合应用在血清动力学和尿液回收率方面产生的差异较小。两种抗生素对肠杆菌科细菌的SBA在1小时后，阿洛西林为1:4至1:8.4，莫拉维酸为1:3至1:8。两种β-内酰胺类抗生素联合使用并未导致对任何菌株的SBA降低；相反，所有肠杆菌科细菌在1小时时SBA均略有增加。从这些结果可以得出结论，阿洛西林和莫拉维酸联合治疗对两种药物的药代动力学或杀菌活性均无不良影响。
